The present invention relates to the field of production, identification and selection of biological binding molecules such as antibodies or fragments thereof, as well as to diagnostic procedures using them in the diagnosis of cancers, in particular malignant B-cell neoplasia. The binding molecules are able to selectively bind to autonomously active or autonomously activated B-cell receptors, the autonomously active or autonomously activated B-cell receptors being characterized by the presence of structural domains to which the binding molecule selectively binds and which are responsible for the autonomously active or autonomously activated state of the B-cell receptors.